Incidence, Prevalence, Mortality, and Disability‐Adjusted Life Years Due to Cancer Among Adolescents Aged 10–19 Years in Iran, 1990–2023: A Trend Analysis of the Global Burden of Disease Study
5 affiliations
- 1Department of Community Medicine, School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
- 2Student Research Committee Shiraz University of Medical Sciences Shiraz Iran
- 3School of Medicine Shiraz University of Medical Sciences Shiraz Iran
- 4Department of Pediatrics, Methodologist, Aliasghar Clinical Research Development Center, School of Medicine Iran University of Medical Sciences Tehran Iran
- 5Research Center for Social Determinants of Health Jahrom University of Medical Sciences Jahrom Iran
Abstract
Background and Aims: Cancer remains a major global public health challenge; however, epidemiological data on the cancer burden among Iranian adolescents remain limited. This study aimed to assess incidence, prevalence, mortality, and disability‐adjusted life years (DALYs) due to cancer among individuals aged 10–19 years in Iran from 1990 to 2023.
Methods: This trend analysis used data from the Global Burden of Disease (GBD) 2023 study. Extracted indicators included incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and DALYs, expressed as age‐standardized rates per 100,000 populations. Temporal trends were evaluated using joinpoints regression, and average annual percent changes (AAPCs) with 95% confidence intervals (CIs) were calculated.
Results: During 1990–2023, 52,942 cancer deaths occurred among Iranian adolescents, including 26,662 (50.4%) in females. Leukemia, brain and central nervous system cancers, and other malignant neoplasms were the leading causes of death. Incidence showed a small but statistically significant increase (AAPC, 0.1; 95% CI, 0.0–0.2 for both sexes), whereas mortality declined (AAPC, −1.2; 95% CI, −1.3 to −1.1), as did DALY rates (AAPC, −1.1; 95% CI, −1.2 to −1.0). In contrast, YLD rates increased substantially (AAPC, 2.0; 95% CI, 1.9–2.1). Non‐Hodgkin lymphoma showed increasing trends in mortality and DALYs.
Conclusion: Although mortality and the overall cancer burden among Iranian adolescents have declined significantly, the concurrent increase in incidence and, particularly, YLDs suggests an epidemiological shift toward a greater nonfatal burden. These findings support the need for comprehensive survivorship care and stronger cancer registration and surveillance systems to address emerging challenges in adolescent oncology.
Related
- Prevalence and incidence of myopia among children and adolescents aged 6–19 years: a prospective cohort study
- Global trends in the burden of malaria: mapping the prevalence, incidence and mortality of Plasmodium falciparum and Plasmodium vivax in the era of climate change and emerging drug resistance.
- Socio-Demographic Inequalities in the Burden of Low Back Pain Across Development Strata: Sex-Specific, Age-Standardized Trends in Prevalence, Incidence and Disability from the Global Burden of Disease Study 2023, 2003-2023.
- Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980–2023) with focus on younger women (0–49 years old)
- The association between disability and mortality among children and adolescents: A systematic review and meta-analysis
BibTeX
@article{azarbakhsh2026incidence,
title = {{Incidence, Prevalence, Mortality, and Disability‐Adjusted Life Years Due to Cancer Among Adolescents Aged 10–19 Years in Iran, 1990–2023: A Trend Analysis of the Global Burden of Disease Study}},
author = {Habibollah Azarbakhsh and Andishe Hamedi and Sanaz Amiri and Seyed Parsa Dehghani and Rozhan Khezri and Fatemeh Rezaei},
journal = {Health science reports},
year = {2026},
month = nov,
doi = {10.1002/hsr2.73397},
url = {https://europepmc.org/article/PMC/PMC13729004},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Incidence, Prevalence, Mortality, and Disability‐Adjusted Life Years Due to Cancer Among Adolescents Aged 10–19 Years in Iran, 1990–2023: A Trend Analysis of the Global Burden of Disease Study
AU - Habibollah Azarbakhsh
AU - Andishe Hamedi
AU - Sanaz Amiri
AU - Seyed Parsa Dehghani
AU - Rozhan Khezri
AU - Fatemeh Rezaei
PY - 2026
DA - 2026/11/01
JO - Health science reports
DO - 10.1002/hsr2.73397
UR - https://europepmc.org/article/PMC/PMC13729004
AB - Background and Aims: Cancer remains a major global public health challenge; however, epidemiological data on the cancer burden among Iranian adolescents remain limited. This study aimed to assess incidence, prevalence, mortality, and disability‐adjusted life years (DALYs) due to cancer among individuals aged 10–19 years in Iran from 1990 to 2023. Methods: This trend analysis used data from the Global Burden of Disease (GBD) 2023 study. Extracted indicators included incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and DALYs, expressed as age‐standardized rates per 100,000 populations. Temporal trends were evaluated using joinpoints regression, and average annual percent changes (AAPCs) with 95% confidence intervals (CIs) were calculated. Results: During 1990–2023, 52,942 cancer deaths occurred among Iranian adolescents, including 26,662 (50.4%) in females. Leukemia, brain and central nervous system cancers, and other malignant neoplasms were the leading causes of death. Incidence showed a small but statistically significant increase (AAPC, 0.1; 95% CI, 0.0–0.2 for both sexes), whereas mortality declined (AAPC, −1.2; 95% CI, −1.3 to −1.1), as did DALY rates (AAPC, −1.1; 95% CI, −1.2 to −1.0). In contrast, YLD rates increased substantially (AAPC, 2.0; 95% CI, 1.9–2.1). Non‐Hodgkin lymphoma showed increasing trends in mortality and DALYs. Conclusion: Although mortality and the overall cancer burden among Iranian adolescents have declined significantly, the concurrent increase in incidence and, particularly, YLDs suggests an epidemiological shift toward a greater nonfatal burden. These findings support the need for comprehensive survivorship care and stronger cancer registration and surveillance systems to address emerging challenges in adolescent oncology.
SN - 2398-8835
ER -